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ABSTRACT
CHARACTERIZATION OF DNA INTERSTRAND CROSS-LINKING AGENTS
BY LIQUID CHROMATOGRAHY-MASS SPECTROMETRY
by
Anahit Marina Campbell
The University of Wisconsin – Milwaukee, 2020
Under the Supervision of Professors Xiaohua Peng and Joseph H. Aldstadt III

This study is to characterize novel reactive oxygen species (ROS)-activated nitrogen
mustard analogues and UV-activated alkylating agents by Liquid Chromatography-Mass
Spectrometry (LC-MS). First, we optimized the instrument conditions to successfully ionize a few
novel binapthalene analogues and methoxybenzene analogues by MS. The highest signal intensity
for compounds 3-10 was observed when atmospheric pressure chemical ionization (APCI) with
an optimized corona needle position of 5mm or 10 mm was used, which led to successful analysis
of compounds 3-10 by MS. Second, we determined pharmacokinetic properties of a drug
compound (FAN-NM-CH3), including animal study, assay development, optimization of MS/MS
instrumental parameter and the development of a calibration model, and finally quantification of
FAN-NM-CH3 in different tissues, including blood, liver, and brain by LC-MS/MS. The results
indicated that the methyl analogue FAN-NM-CH3 showed a t1/2 of 8.84 min that is two times of
the parent compound CWB-20145 with a t1/2 of 4.92 min. The results suggested that introduction
of an alkyl group (CH3) greatly increases in vivo duration, which is an important guide for further
modification. The rate of elimination for the parent compound CWB-20145 in the blood is two
times faster (Erate = 0.141 min−1) than that of FAN-NM-CH3 (Erate = 0.078 min−1). FAN-NM-CH3
showed an area under the curve (AUC) of 16.25 µg•min/mL, which is significantly higher than

ii

that of CWB-20145 (10.88 µg•min/mL). Further in vitro microsomal stability studies revealed that
FAN-NM-CH3 is significantly more stable in human (t1/2 = 77.06 min) than in mouse (t1/2 = 33.0
min). The human microsomal stability of FAN-NM-CH3 supports its design as a human
therapeutic.
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CHAPTER 1. INTRODUCTION

Mass spectrometry (MS) is perhaps the most widely used analytical method in the
pharmacological context of drug development. It is an analytical technique where ions are
separated and then detected by means of their mass to charge ratio (m/z). The popularity of MS
is due to the fact that it is highly sensitive, selective, and can be hyphenated to other techniques
such as liquid chromatography (LC), ultra violet (UV) absorption spectroscopy, nuclear
magnetic resonance (NMR) spectroscopy, and several others. This work will focus on the
application of single quadrupole (MS) and triple quadrupole (MS/MS) mass spectrometry for
analysis of DNA alkylating agents.
LC-MS analysis of the drug compounds consists of sample pretreatment, separation, and
detection. Each component has effects on factors such as accuracy, precision, selectivity, and
sensitivity of the results (1). While sample preparation and separation are generally similar
processes among various drug compounds, the difficulty lies in the detection of the compounds
because of the fact that the compounds must be ionized for detection to occur with MS. This
work will describe the challenges pertaining to the ionization of alkylating agents containing
halogens, experimental design for in vitro and in vivo MS/MS analysis, and finally the design of
a novel LC-NMR/MS method that will allow for the high-throughput determination of drug
compounds while providing complimentary structural information by NMR as well as MS.

1.1 Halogenated ROS-Activated DNA Interstrand Cross-linking Agents
1.1.1 Background
1

During WWI, alkylating agents were used not as therapeutic drug compounds but as a
warfare agent known as nitrogen mustard gas. Nitrogen mustard reacts with the N7 position of
purine bases guanine and adenine in the double strands of DNA and induces DNA interstrand
cross-links (ICLs), thus preventing the separation of DNA double helix. Nitrogen mustard has
been used as a chemotherapy drug in the 1940s. Early examples of such drugs had been modified
for decreased toxicity including chlorambucil and busulfan, which have been approved by the
FDA to treat various types of cancer (2).
Most cancer diseases have to be treated with systematic chemotherapy or radiotherapy,
which has negative adverse effects for the patient due to its lack of selectivity towards the tumor
cell. Targeting tumor-specific conditions, such as reactive oxygen species (ROS), can result in a
drug that is more selective to tumor cells and reduce adverse effects. Many tumor cells are under
oxidative stress and have higher level of ROS than healthy cells (3). Recently, Peng’s group has
developed a series of H2O2-activated DNA interstrand cross-linking agents that showed selective
cytotoxicity towards cancer cells but spared the normal cells. For example, compound 1 (CWB20145) and compound 2 (FAN-NM-CH3) (Scheme 1) are activated by H2O2 to induce DNA
interstrand cross-link (ICL) formation. Moreover, the compounds discussed are neutrally
charged, thus improve cell membrane diffusion and drug efficacy (4-7). Peng’s group also
developed a series of photo-activated DNA ICL agents. For example, compounds 3 and 4
(Scheme 2) can be activated by 350 nm light (hv) to generate free radicals that are then oxidized
to the carbocations directly producing DNA ICLS (7). Regardless, both types of triggers result in
the compounds with better DNA cross-linking efficiency (4-7).

2

1

2

Scheme 1: The structures of Modified Nitrogen Mustard Analogues 1 (CWB-20145) and 2
(FAN-NM-CH3).

3

4

5

6

Scheme 2: The structures of Binapthalene Analogues 3, 4, 5, and 6 (including naphthalene
precursors 5 and 6).

The general mechanism of function for these DNA ICL agents is to block DNA
transcription and replication by cross-linking the DNA double helix strands. This in turn results
in the death of cancer cells (8). Compounds 1 and 2 consist of a H2O2-responsive moiety (a
trigger, boronic acid or ester) that reacts with H2O2 and an effector that acts as DNA cross-linker
(e.c. nitrogen mustard). The effector is deactivated by the electron withdrawing boronate ester
3

group. However, this deactivation can be reversed if the boron group is replaced by a donating
OH group in the presence of H2O2, therefore increasing the electron density of the aromatic ring
and activating the nitrogen mustard. This facilitates DNA ICL formation.

Figure 1. Activation Mechanism of 1 by H202 to form DNA ICLs, where OR = OH (5).

Although there are many examples of FDA-approved ICL prodrugs, many still contain
low selectivity (and thus adverse effects), poor efficacy, among other shortcomings. In the case
of the compounds developed by previous collaborators in our group, it was found that compound
1 and compound 2 hold promising potential for cancer cell lines such as SR (leukemia), NCIH460, (non-small-cell lung cancer), and MDA-MB-468 (breast cancer). It was also
determined that the aromatic substituents on compound 1 greatly affected the ICL efficiency.
The results suggested that avoiding a bulky protecting group and introduction of a weak electron
donating group is beneficial for selectivity (5).

4

7

8

9

10

Scheme 3: The structure of Methoxybenzene Analogues 7, 8, 9, and 10.

In addition, compound 1 and compound 2 show potential as being a more effective
treatment option for triple negative breast cancer (TNBC) than FDA approved drugs such as
chlorambucil (7). Furthermore, while there have been great strides in the development of ROS
activated prodrugs, especially towards their in vitro cytotoxicity and selectivity, little work has
been done on the in vivo efficacy as well as selectivity. Lastly, in vivo studies provide that there
are no adverse effects from the therapeutic dosing of compound 1 and compound 2, which is not
the case for the FDA approved drugs such as chlorambucil or melphalan. Lastly, 7, 8, 9, and 10
(Scheme 3) are precursors for some new novel photo-activated DNA cross-linking agents (5), the
mass of which were confirmed by mass spectrometry, during this study. Further information on
ROS-activated prodrug analogues developed by group collaborators can be found in the
references (4-7).

1.2 Research Approach

This study presents the LC-MS quantification of several alkylating agents synthesized by
5

collaborators in the group. We describe the analytical challenges associated with compounds 1
and 2 and present solutions that enable ionization to occur. Additionally, we present
pharmacokinetic data of compound 2 that showed advantages over the parent compound 1, such
as longer duration time, slower elimination rate, and higher absorption. Lastly, this work will
describe in detail a proposed hyphenated instrumental design that allows for the high-throughput,
convenient, and information-rich analysis of such drug compounds using LC, NMR, and MS.

1.2.1 Liquid Chromatography (LC)

LC is the most common and versatile method of separation for biological analysis in the
context of drug development due to its orthogonality. Although HPLC methods are commonly
used, UPLC (ultra-high pressure liquid chromatography) is becoming more common because it
is more efficient. The most common type of LC used in pharmaceutical investigations is
reversed-phase liquid chromatography (RPLC). This type of separation involves the elution of
the liquid sample which is pumped at high pressures through an injection port that leads the
sample into a heated column where it is separated. The detector then processes the signal and
displays the peaks in a spectrum by the order of elution which for RPLC, more polar compounds
elute first and more non-polar compounds elute last. RPLC-MS mobile phases typically consist
of water, methanol, or acetonitrile and often times additives that promote positive ionization,
such as ammonium acetate, ammonium formate, acetic acid, and formic acid or additives that
promote negative ionization such as ammonium hydroxide (9). It is the ionization of these
compounds that is key to mass spectrometry and a challenge that will be discussed in this work.

1.2.2 Quantitation by Mass Spectrometry (MS)
6

MS detection is well suited to function with reversed-phase UPLC (hereafter referred to
as LC), due to the fact that compatible solvents to elute the sample and additives in the solvent
assist the ionization process (9). A mass spectrometer is a detector that is selective, sensitive, and
can be used to analyze a variety of compounds. In addition to single quadruple mass
spectroscopy (see Figure 1-1), tandem mass spectrometry (see Figure 1-2) is one of the most
powerful tools for the analysis of drug compounds. A single quadrupole MS has four parallel
rods, two positive and two negative. The opposing rods are attracted to one another and when a
radio frequency (RF) voltage and direct current (DC) are applied to a pair of opposing rods, the
charged ions travel between the rods. Ions of a particular m/z will make it to the detector for a
certain voltage to RF ratio. Other ions will collide with the rods ad not reach the detector. Triple
quadruple MS (MS/MS) includes three sets of the quadruples, the first set (Q1) serving as a mass
filter, the collision cell (Q2) where the ions collide with neutral gas for fragmentation, which
then enter the second (Q3) serving to filter fragment ions based on the parent peak selected in the
first set. Other components include sample separation (HPLC) and a detector The instrument is
operated in multiple reaction monitoring (MRM) mode which can determine the molecular mass
of the ion as well as the fragment ions. Because of this additional layer of information, the
instrument has higher sensitivity as well as selectivity than just a single MS (9).
For quantitation, an internal standard is typically used to correct for instrument variations.
A suitable internal standard (IS) is one that is structurally similar and in the same mass range as
the analyte, so that the IS undergoes a similar ionization process as the analyte. One major issue
that plagues mass spectrometry is ion suppression, which is caused by less volatile compounds
that affect the droplet formation and evaporation process. This phenomenon thus varies the
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amount of charged ions that are produced and therefore causes errors in the analysis. Ion
suppression can be avoided by carefully selecting various additives to use in the LC mobile
phase. Weaker acids (acetic, formic, etc.) can be used in the place of stronger acids (TFA), for
example (10).
Other considerations include the fact that sample, especially biological samples, cannot
be injected directly into the LC-MS instrument and instead must undergo sample preparation to
remove matrix effects, preconcentrate the sample, and otherwise ensure that the sample that can
be analyzed. Of the methods available, solid-phase extraction (SPE), is commonly used because
it is versatile a wide range of cartridges and solvent systems are commercially available. Another
option is liquid–liquid extraction (LLE) followed by rotoevaporation to remove the organic
phase. A detailed discussion of sample preparation for the analysis of alkylating agents is
discussed in the next section. sample preparation for the analysis of alkylating agents is
discussed in the next section.

1.3 Characterization of Novel Halogenated Alkylating Compounds by Mass Spectrometry

Alkylating agents, as expressed previously, bind to nucleophilic moieties and are
cytotoxic to cancer cells once they cross-links DNA strands. Literature has demonstrated a
variety of sample preparation and analysis conditions for particular types of alkylating agent. For
example, SPE (C18 cartridges) were used to extract cyclophosphamide and its metabolites from
human plasma in a study. A faster and simpler method of LLE (methanol‐acetonitrile) was used
for protein precipitation and resulted in high recoveries (89%–100%) of cyclophosphamide and
4‐hydroxycyclophosphamide from plasma samples. Limits of detection of 0.2 ng/mL of agents
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(cyclophosphamide and ifosfamide) have been achieved in urine (11-14). When it comes to
analysis of an unstable compound as well as one that lacks chromophores, oxazaphosphorines,
LC-MS was the appropriate choice for the analysis as compared to GCMS or LC-UV (15). In the
case of chlorambucil, a nitrogen mustard derivative, although several LC-UV methods have been
presented, LC‐MS/MS methods have proven to be not only more rapid, but at least 10x more
sensitive in plasma and urine samples (1).
In the case of our group’s novel alkylating agents, another issue needed to be consideredis ionization. Even after adequate sample preparation, solvent system optimization, and
instrument consideration, the challenge was achieving ionization of the compounds.
Experimental design for alkylating agents requires the careful selection and corona needle
optimization, as described in the following section on ESI, APCI, and DUIS ionization modes.

1.3.1 Electrospray Ionization (ESI)

Electrospray ionization (ESI) (see Figure 1-3) is an ionization technique for MS where a
liquid sample is converted into nebulized aerosol composed of tiny charged droplets which are
then charge separated. The droplets undergo high electric potential between the liquid sample (in
a capillary) and the counter electrode. In this stage the radius of the droplets will decrease as the
solvent evaporates, and due to the Rayleigh limit, Coulombic forces overcome the surface
tension of the droplet resulting in “Coulombic fission.” In this manner, the ions enter the gasphase. Advantages of ESI include the “soft” ionization (resulting in multi-charging and thus an
advantage for large molecules), high ion transmission, and high sensitivity even at low flow rates
(16).
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The basis of ESI was first described in the context of MS in the 1960s by Dole in his
group’s analysis of polystyrene. Variations of the method evolved, but in the 1980s, Fenn
successfully developed an efficient ESI interface to MS for the first time, earning him the Nobel
Prize in Chemistry in 2002 (16). Further advances included Bruins’ addition of a nebulizing gas
to create a charged aerosol in 1987 (17) and most recently, the coupling of APCI with ESI (18).

1.3.2 Atmospheric Pressure Ionization (APCI)

Atmospheric pressure chemical ionization (APCI), see Figure 1-4, is an ionization
technique for MS consisting of an inlet capillary within a nebulizer capillary. It is in this heated
capillary that nebulization occurs with the auxiliary gas serving to prevent interactions between
the wall and the analyte. A corona discharge needle causes the ionization process to occur. The
ionization can occur in positive mode where a proton transfer, charge transfer, or adduct
formation can occur. The ionization can also occur in negative mode where proton abstraction,
electron capture or anion attachment can occur (9). There are advantages and disadvantages to
the APCI mode of ionization. One advantage is that since APCI is a “soft” ionization technique
in that the mass spectra are relatively simple (16). In addition, matrix effects are not as
pronounced as is the case in ESI. However, selection of a solvent system to use with APCI can
be difficult because of preferential ionization of solvents with high proton affinity (19).
Shahin was the first to utilize APCI as an ionization source for MS in the 1960s, where a
platinum wire was used as the anode in a discharge chamber (20). In the 1970s, Horning and coworkers developed the corona discharge needle when the LC was coupled to MS (21) which is
the interface familiar today (the heated tube nebulizer was introduced later). Finally in the 1990s,
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dual ionization mode (ESI and APCI) was achieved by switching between the two ionization
modes in the same experiment (22). Recent advancements in APCI include various interface
heating methods. Such designs include gradient heating to prevent the ion source from
recirculating the atmosphere (23).
The theory of APCI is that the most stable reagent ion will be formed, which in turn will
ionize the analytes of interest. If the reagent ion is more stable than the ionized analyte, the
analyte ion will not form because the reaction will not be favored. In positive mode, RH+ is the
reagent ion and B denotes an analyte:
RH+ + B ⇌ BH+ + R
The protonation of the analyte will only proceed if the gas phase basicity (GB) for B is
higher than the GB for the reagent ion RH+ . The gas phase basicity is defined as the change in
Gibbs free energy for the reaction (16):
B + H+ ⇌ BH+
Thus the solvent system can influence ion stabilities and therefore ionization efficiency.
For example, in reference to proton affinities (positive mode) or gas-phase acidity (negative
mode) of solvents (and additives), methanol has a lower proton affinity than acetonitrile (754 kJ
mol-1 vs 779 kJ mol-1, respectively. Therefore, methanol would be a more suitable choice as an
LC solvent if the proton affinity of the analyte is low (24).

1.3.3 Dual Mode Ionization

Different types of samples require different ionization modes. For example, for non-polar
compounds, APCI is a better choice because in ESI, the non-polar compounds tend to not
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evaporate and thus will not undergo the ionization process. For polar compounds, ESI is a more
appropriate ionization choice because APCI occurs in the gas-phase, and thus the solvent does
not need to be polar for ionization to occur as in ESI. A diagram of the polarity regions most
appropriate for each ionization source is depicted in Figure 1-5 as well as Table I (1), depicting
various studies with their respective ionization conditions. Some compounds or mixtures require
dual-mode ionization, i.e., both ESI and APCI simultaneously, as illustrated in Figure 1-6 and
depicted in Figure 1-7 as described from a case study (25). The disadvantage however is that the
degree of sensitivity is less than when they are used individually (26).

1.4 Theory of In Vitro Microsomal Stability Studies and Pharmacokinetic
Studies
1.4.1. In Vitro Microsomal Stability Study of Drug Compound 2 (FAN-NM-CH3)

In-vitro stability studies allow for the prediction of a drug compound's potential
metabolic clearance by liver enzymes, but without the cost and demands of an in vivo animal
study (2). To calculate first-order rates, we calculate the half-life (t0) using the following
equation:
(t0)min = ln(2)/k = 0.693/k
where k is the first-order rate constant. We then linearize the data with the following
transformation:
(t0)
In the case of first-order half-life, the half-life decay is constant, as seen in Figure 1-8 in an
example diagram (27). The hepatic metabolism is a key initial step as it is a good indicator of in
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vivo pharmacokinetics. The assumption is that hepatic metabolic clearance is the major
mechanism of clearance (28), as in the case shown below with 2.

1.4.2 In Vivo Pharmacokinetic Study of Compound 2 (FAN-NM-CH3)

The experiments after the in-vitro stability study dealt with in-vivo pharmacokinetics
(PK), or the determination of how the in-vivo model handles a drug compound in the context of
absorption, distribution, metabolism, and elimination. In the case of compounds derived from
nitrogen mustard drugs, a slower clearance of the drug is desired (28). Such studies can help
assess the concentration-time curve using the following ratio:

AUC/MIC
where AUC is "area under the curve" and MIC is the "minimal inhibitory concentration". This
ratio is a key measure of drug efficacy (29).

1.5 Instrumental Hyphenation

1.5.1 Analysis of HPLC-UV-NMR-MS Interfacing Scheme

As this work has already presented, MS is a critical tool in the drug development process.
It allows for compounds to be accurately determined. However, MS has the disadvantage of
lacking structural data. On the other hand, proton NMR is also a powerful tool for drug
development as it a non-destructive method to provide structural information to allow distinguish
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stereo-isomers however NMR has limitations as it is a tool that cannot compare to the sensitivity
and selectivity that MS can offer and is not a suitable method if the analyte's functional groups
are NMR-silent (i.e., lacking protons or able to exchange protons with the solvent) (30). It can be
concluded then that NMR and MS are complimentary techniques, and both are necessary in the
study of drug compounds. Yet drug development requires high-throughput capabilities and adds
an additional challenge because of the complexity of the samples. Therefore, much research has
occurred in the past several decades to interface NMR and MS.
More recently, splitting the flow to the NMR and MS while coupling preconcentration
methods (e.g., SPE) upstream, and in-parallel analysis (31). There are two types of methods of
hyphenation, the first being in-series hyphenation, which is one detector after another, while inparallel hyphenation introduces the sample to the detectors simultaneously. With in-series
hyphenation, the disadvantages include greater difficulty in ascribing the results to a given
detector and more frequent leaks because of the large pressure difference between the NMR and
MS. With in-parallel hyphenation, advantages include that the analysis can occur simultaneously
although there is a delay with completing the NMR measurement (32-33). Examples of both
coupling method schematics are found in Figure 1-9 from work by Gebretsadik et al (34).
Summarizing timelines (Figure 1-10 (a) and (b)) of the historical developments of hyphenated
NMR are presented (31).
LC-NMR has several advantageous when compared to conventional NMR. Proton NMR
spectra can be acquired quickly and without spectral interferences if the analyte is isolated in
pure form. There are however, obvious concerns about a hyphenated LC-NMR method (35). One
major concern with coupled NMR and MS is that there can be significant solvent suppression of
the NMR signal if either non-deuterated solvents are used or if the suppression is not mitigated
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through some other means such as preconcentration. Additionally, if the solvent contains solvent
additives, there may be adverse effects such as the deposition of salts in the NMR flow cell, e.g.,
with the use of sodium phosphate or TFA (trifluoroacetic acid) which may result in ion
suppression for acidic compounds. Formic acid is an additive that avoids these issues because it
promotes positive ionization. Simply using deuterated solvents holds issues as well because H/D
exchange with the analyte may occur, which would result in inaccurate measurements (32).

1.5.2: LC-NMR Past Improvements

Coupling LC to both NMR and MS, whether in-series or in-parallel, offers the potential
for an immense amount of information to be gathered in a single experiment. In reality however,
there are difficulties because of the large sensitivity difference (103 – 106) between the two
detectors, because the MS is far more sensitive than the NMR. In addition, the acquisition time
for the MS is far shorter than for the NMR (36). Furthermore, there are trade-offs to choosing an
in-series or an in-parallel instrumental design. Lommen et al. were able to overcome these
challenges in an experiment, the data for which is shown in Figure 1-11 (37). In this experiment,
the parent mass as well as the fragments were determined selectively by MS as compared to UV.
The first inset chromatograph depicts a spectrum by UV analysis. Directly below is a mass
spectrum of the m/z = 301 of only quercetine fragments (below),

selected by an NMR measurement. The last inset depicts the loss of an ion of m/z = 162, thus
only peaks with a C6 sugar appear in the spectrum. It can be concluded that NMR and MS data
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are complimentary, and by following up with further NMR analysis post MS analysis, co-eluting
peaks such as those of compounds glucopyranosid and galactopyrandosid, was determined (37).
Nevertheless there have been successful applications of LC-NMR-MS in drug studies.
For example, Paracetamol (acetomeaphen) (below)

was determined in urine using RPLC-UV-NMR-MS, where NMR and MS spectra were collected
in parallel. The mobile phase solvents were non-deuterated acetonitrile in D2O with deuterated
trifluoroacetic acid and the LC eluent was split 98:2 to the NMR:MS. A schematic of the inparallel instrumental coupling including NMR and MS can be seen in Figure 1-12 (33). The
authors used a combination of two measurements to deduce information about the endogenous
drug metabolites. These experiments included an initial run with identification of the pseudomolecular ion (MD+) at m/z 334 and then a second run with the addition of methanol:acetic acid
to enable the deuterons to exchange with the hydrogen atoms. MH+ ions were produced for all of
the fragments of the analyte and the exchanged hydrogens distinguished by the mass difference
(33).
There have also been studies of dihydroquinoxalinecarboxylate (below),

a drug used to treat HIV, in urine. The method used gradient elution RPLC (acetonitrile in D2O
with acetic acid), and LC fractions were collected on-line in a loop collector, and run in-series to
a proton NMR and then to an ion trap MS. The schematic diagram depicting in-series NMR and
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MS with a fraction collector down-stream is presented in Figure 1-13 (38). The same group also
carried out the measurement in reverse, i.e., RPLC-ion trap MS-NMR (Figure 1-14) (39). The
LC-MS-NMR design was studied with a drug used to treat bipolar disorder called
triazolopyridine. By determining the masses of the peaks of interest, the fractions could then be
stored for stopped-flow analysis with the NMR, on-line (39).
LC-NMR-MS/MS has also been reported by Scarfe and co-workers. Once again, a
solvent gradient of acetonitrile in D2O with acetic acid was employed along with an ion trap and
ESI MS/MS. The authors determined the major metabolite in the urine sample to be a sulphate
conjugate, which are considered "NMR-silent" (due to a lack of protons) and in addition MS
could not determine the actual position of substitution of the aromatic ring of the metabolite, that
NMR could if the compound was not silent. This case proves clearly how beneficial hyphenated
methods can be because neither HPLC-NMR nor HPLC-MS alone were able to determine the
metabolites. Instead it was the complimentary information from the HPLC-NMR-MS method
that allowed for accurate determination (30). Another study showed how stereochemistry could
be determined by the NMR in a hyphenated system, in which ibuprofen in urine was metabolized
to glucuronide diastereomers, which were not distinguishable by MS but were by NMR, the
results of which can be found in Figure 1-15 (40) and the in-parallel schematic diagram for this
work is shown in Figure 1-16 (40).

NMR is a powerful analytical tool that provides vital information to aid in the prediction
of the chemical structure of a compound (9). LC-NMR was first described in the 1970s, and
there has been an increasing interest in it over the last two decades because of improvements
made to NMR instruments. For example, Watanabe and Niki first reported a successful LCNMR design in 1978 (Figure 1-17) (41) by using a thin-walled Teflon tube (1.4 mm in inner
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diameters) to serve as a continuous-flow cell. The authors used deuterated solvents to evade
solvent suppression to measure various drug compounds. The study also presented various areas
that needed improvement including sensitivity, as the sample had to be run hundreds of times to
achieve an equivalent signal to noise ratios for samples of different concentration (41). Two
years later, the first design of on-flow LC-NMR was reported by Dorn et al. using a novel NMR
flow cell insert (Figure 1-18) (42) to analyze jet fuel sample mixtures. The optimized insert had a
vertical orientation to prevent air bubbles from becoming trapped in the cell. The cell was also
tapered at both ends of the insert to prevent eddy diffusion by minimizing particle size (42).
Building upon this work, Laude and Wilkins (1984) further optimized the insert design by
incorporating a stainless-steel column, minimizing the transfer line and thus increasing resolution
and sensitivity due to the minimization of dead volume, as seen in Figure 1-19 (43).
Another problem that had to be resolved that of the mobile phase, which earlier had been
fairly non-complex in order to avoid potential interfere with the sample with the use of two
solvent resonance changes during a gradient elution, and of course the detection limit.
Smallcombe in 1995 reported a technique to overcome these issues by WET (“water suppression
enhanced through T1 effects”), where selective pulses are applied at the solvent's resonance and
then this is followed by field gradients that are pulses to diphase (or minimize) the residual
magnetization produced by the solvent. This allows for the selection of a particular
magnetization and not of others. This can be seen in the spectra results in Figure 1-20 (44), with
the unsuppressed and suppressed resonance of acetonitrile solvent (44).
Low sensitivity and issues with solvent complexity was also addressed through the
implementation of smaller flow cells and the use of cryogenic probes. This was reported by
Sweedler et al. in the late 1990’s with their development of a microcoil flow cell probe, which is
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depicted in Figure 1-21 (45). For the cryogenic microcoil probes, the NMR cell was cooled to
20° C, thereby improving sensitivity (Figure 1-22) (45). This first demonstration of continuousflow technique was used to analyze an amino acid and peptide mixture and was able to detect
analyte concentrations of 750 ng/mL (ppb). In addition, separation was achieved in under 10 min
and NMR spectra were collected with 12 s of time resolution. Lastly, the authors also performed
stopped-flow experiments to collect 2D COSY spectra (45).
Not only are there various instrument coupling methods, but the connection of the LC
component to the NMR or other instrument is much more than just connecting some capillary
tubing from the LC column, but instead requires an automated way to ensure the most
reproducible and reliable results in addition to ease of use. A switching value interface can
involve continuous flow of the sample through the NMR as the signal is acquired, or “on-flow,”
or it can be measured while the flow is stopped and the sample is in the NMR cell. There are two
types of designs for this purpose: “(direct) stop-flow” and “loop storage/loop transfer”. In “stopflow,” the chromatographic separation is interrupted for an NMR measurement whereas with
“loop storage/loop transfer,” the chromatographic peaks are stored as they elute into a loop
system until a measurement is taken with the NMR. In the case of the design research reported
herein, we combine “on-flow,” “stop-flow,” and a “loop transfer” to capture the eluted sample in
the NMR flow cell, and then acquire the spectra while the sample is static within the NMR cell
and divert the rest of the LC eluent to waste (36).

1.5.3 Brief Overview of NMR Theory

Nuclei spin at an angular momentum “p” and thus this charged nucleus creates a
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magnetic field. A magnetic moment “µ” is positioned along the spin’s axis and is equal to p:.
µ = γp
where γ is the proportionality constant specific to the nucleus. If a magnetic field “B0” is applied
to a spinning nucleus, µ becomes oriented in either of the directions of the field. When B0 is
absent, the quantum states of the nucleus are the same. Thus the strength of the magnetic field is
a principle component to NMR and its strength dictates the strength of the observed signal:
(Nj/N0) = 1 - (vhB0)/(2πkT)
where Nj and N0 are the number of protons present in the higher and lower energy states,
respectively, v is the frequency, h is Plank’s constant, B0 is the applied field strength, k, again, is
Boltzmann’s constant, and T is absolute temperature. A depiction of the nuclei under the
conditions described above can be found in Figure 1-23 (9).
The advantages of using NMR are plentiful. First, NMR is non-destructive and can detect
low molecular weights of molecules. In addition, NMR provides complimentary information to
the MS such as chemical shifts, multiplicity, integrals, intermolecular relationships, and dynamic
processes (46). The disadvantages include the sensitivity of NMR, which means that large
amounts of analyte are required as compared to MS. For example, NMR would require at least
µg/mL concentrations whereas MS only requires ng/mL concentrations to produce an adequate
signal. As noted above, this issue can be addressed by splitting the flow from the LC to separate
tubing of different diameter to direct > 99% of the eluting volume to the NMR while 1% would
be directed to the MS (34).

1.5.4 NMR Spectra
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One advantage of proton NMR is that the peak area can be directly quantified as the
amount of nuclei that produce the peak, provided of course that this peak does not overlap with
another peak. The solvent plays the role of a standard shift, since the rest of the peaks can be
standardized to that of the known solvent peak, for the purpose of quantification.
Chemical shifts arise from the fact that hydrogens have different environments and
number of hydrogens that belong to each signal can be determined by the integration of the
peaks.

For example, the molecule shown has two different proton environments and thus two distinct
For a simple example, consider Methyl Glyoxal shown above, which has two different proton
environments and thus two distinct signals in its NMR spectrum — one for the hydrogens on the
CH3 and one for the terminal CH. Following the “n+1 rule,” the neighboring carbon to the CH3 is
a C with no hydrogens. Thus the signal produced for the CH3 would be a 0+1 or a singlet “s”
with an integration of 3 hydrogens. The other signal from the CH would also be a singlet,
however with an integration of 1 hydrogen. Both signals would be found down-field on the
spectrum because the electronegatively of their environments are high from the nearby oxygens,
and therefore different magnetic fields are necessary to achieve resonance at a set frequency (9).

1.6 Research Goals

The goals of this project were to:
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1.Develop an LC-MS method to analyze the novel FAN-NM-CH3 compound.

2. Modify the method for the analysis of pharmacokinetic samples.

3. Design an on-line LC-NMR-MS system.
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1.7 Figures and Tables

Figure 1-1. Schematic diagram of a single quadrupole MS (48).
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Figure 1-2. Schematic diagram of a triple quadruple MS (MS/MS) (47).
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Figure 1-3. The electrospray ionization process (18).
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Figure 1-4. Schematic diagram of an atmospheric pressure chemical ionization source (49).
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Figure 1-5. A guide to the polarity regions most appropriate for each ionization source (51).
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Figure 1-6. A schematic showing the DUIS ionization source (29).
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Figure 1-7. Comparative data of DUIS mode ionization (25).

29

Figure 1-8. A graphical depiction of first-order half-life (29).
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A

B

Figure 1-9 (a) and (b). Schematics of in-series (LC-NMR-MS) and in-parallel LC-NMR/MS
hyphenation (Adapted from Gebretsadik, T, et al) (34).
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Figure 1-10 (a) and (b). Timeline of historical developments with hyphenated NMR techniques
(31).
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.
Figure 1-11. LC-NMR/MS work by Lommen et al. to measure glycosides (37).
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Figure 1-12. A schematic demonstrating in-series and in-parallel hyphenation (33).
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Figure 1-13. A schematic of LC-NRM coupled with ion-trap MS detection (38).
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Figure 1-14. A schematic of LC- ion-trap MS coupled with NMR (39).
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Figure 1-15. A study depicting information obtained from NMR and MS to determine the
structure of a drug metabolite. A. is a 500 MHz proton NMR spectrum, B. is a spectrum obtained
ESI MS, and finally C. is MS/MS (40).
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Figure 1-16. A schematic of LC-NRM-MS/MS detection (40).
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Figure 1-17. The first novel example of LC-NMR (41).
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Figure 1-18. A diagram of a novel NMR Teflon probe (42).
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Figure 1-19. A diagram of a stain-less steel NMR probe (43).
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Figure 1-20. A schematic diagram of an on-line flow system developed for the LC-NMR
method (45).
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Figure 1-21. A schematic diagram of a novel microcoil NMR flow probe (45).
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Figure 1-22. Spectra of a WET stopped-flow experiment involving a 10 mM sucrose in
CH3CN:D2O (50:50). While the spectrum at the stop depicts unsuppressed spectrum with
significant solvent resonance at 1.95 ppm, the bottom spectrum includes the WET technique of
solvent suppression (44).
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Figure 1-23. A depiction of a spinning nuclei under an applied field (9).
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Table I: Studies of anti-cancer drug metabolites using ESI MS (1).
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CHAPTER 2. EXPERIMENTAL
2.1 Experimental Conditions of Halogenated Aromatic Compounds as
UV/ROS-Activated DNA Interstrand Cross-linking Agents by Liquid
Chromatography Single Quadruple Mass Spectrometry
2.1.1 Chemical Reagents and Compounds
All solvents used in this work (including water) were LC-MS grade and were used
without further purification. Water, acetonitrile (MeCN), methanol (MeOH), and formic acid
(HCOOH) were obtained from Fisher Scientific (Pittsburgh, PA, USA). Lastly, 2 mL glass MS
autosampler vials were purchased from (Shimadzu Corp., Kyoto, Japan).

2.1.2 Sample Preparation

All compounds analyzed were provided by other group members.

Binapthalene Analogues 3, 4, 5, and 6 (including naphthalene precursors 5 and 6)
A concentration of ~0.5 mg/mL sample of 3 and 4 was prepared for LC-MS
analysis. This was done by dissolving the respective compound in a 2:1 ratio of LC-MS grade
MeCN:MeOH and vortexing the solution for 10 s, then sonicating the solution for 10 min and
vortexing for another 10 s. A dilution of the100 µM sample was prepared for LC-MS analysis.
After the samples were prepared in vials, the vials were wrapped in aluminum foil to prevent
photodegradation of the compound.
A 1.0 mM sample of 5 and 6 was prepared for LC-MS analysis. This was done by
dissolving the compound in LC-MS grade acetonitrile and vortexing the solution for 10 s, then
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sonicating the solution for 10 min and vortexing again for 10 s. Dilutions of 250 µM and 100 µM
were prepared from the stock.

3

4

5

6

Methoxybenzene Analogues 7, 8, 9, and 10
A 1.00 mM sample of 7, 8, 9, and 10 was prepared for LC-MS analysis. This was
done by dissolving the compound in LC-MS grade MeOH and vortexing the solution for 10 s,
then sonicating for 10 min and then vortexing again for 10 s. Dilutions of 100 µM and 10 µM
were also prepared, however they were not concentrated enough to achieve a distinct signal on
the MS instrument.

7

8

9

2.1.3 Mobile Phases for LC-MS
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10

Naphthalene precursors 5 and 6
The mobile phase was composed of water with 0.1% HCOOH (v/v) (A) and MeCN
(B). The gradient programming was the following: 50% B (0.0 min) → hold at 100% MeCN B
(6 min) → return to 50% B (2.5 min) → hold at 50% MeCN B (3.5 min). The column
ttempérature was 40 °C.

Binapthalene Analogues 3, 4
The mobile phase was composed of water with 0.1% HCOOH (v/v) (A) and MeCN
(B). The gradient programming was the following: 10% B (0.0 min) → 100% MeCN (8.0 min)
→ hold at 100% B (12.0 min) → return to 10% B (20.1 min) → hold at 10% B (18 min). The
column temperature was 40 °C.

2-Methoxy Analogues and Starting Material 7, 8, 9, and 10
The mobile phase was composed of water with 0.1% HCOOH (v/v) (A) and MeOH
(B). The gradient programing was the following: 20% B (0.0 min) → 40% MeOH (1.0 min) →
60% B (2.0 min) → 80% MeOH (3.0 min) → hold at 90% B (2.0 min) → return to 20% B (7.0
min). The column temperature was 40 °C.

2.1.4 Instrumentation

Naphthalene precursors 5 and 6
Qualitative LC-MS (Shimadzu Model 2020, Shimadzu Corp., Kyoto, Japan) (Figure 2-1
(a)) analysis was employed to confirm the identity of the compounds. An Agilent TC-C18
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column (4.6 mm x 250 mm, 5 µm particle size, Agilent Technologies, Santa Clara, CA, USA)
was used for separation. The ionization sources for the 2020 model include ESI, APCI, and dual
mode (DUIS), as seen in Figure 2-1b. The sample (10 µL) was injected into the LC-MS
instrument in APCI mode, with the corona discharge needle set to an optimal position of 5 mm.
Images of the corona discharge needle setting can be seen in Figure 2-2 (a) and (b). The MS was
operated with the following method factors:
● heat block temperature at 400 °C
● drying gas flow rate of 15 L/min
● desolvation line temperature of 250 °C
● nebulizing gas flow rate of 1.5 L/min
● interface voltages of 4.5 kV
● positive or negative: APCI modes
The LC and column were operated with the following factors:
● gradient elution flow rate of 0.7 mL/min
● column oven temperature of 40 °C
● 200-400 nm UV-VIS molecular absorption detection
All experiments were conducted in duplicate with blank solvent injections in between each set of
duplicate trials.

Binapthalene Analogues 3 and 4
Qualitative LC-MS (Shimadzu 2020, Shimadzu Corp., Kyoto, Japan) analysis was
employed to confirm the identity of the compounds. 10 μL of the sample was injected into the
LC-MS instrument. The ionization mode was ESI. The MS was operated with the method
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parameters as described for Brominated and Chlorinated Naphthalene Analogues.

2-Methoxy Analogues and Starting Material 7, 8, 9, and 10
Qualitative LC-MS (Shimadzu 2020, Shimadzu Corp., Kyoto, Japan) analysis was
employed to confirm the identity of the compound. An ultra-high pressure column, (ACQUITY
CSH C18, 2.1 mm × 50 mm, 1.7 µm particle size, Waters Corp, Milford, MA, USA), was used
for separation. The sample (5 μL) was injected into the LC-MS instrument. The ionization mode
was optimized to be dual ESI/APCI mode with the corona discharge needle set to an optimized
position of 10 mm.
● heat block temperature at 400 °C
● drying gas flow rate of 15 L/min
● desolvation line temperature of 250 °C
● nebulizing gas flow rate of 1.5 L/min
● interface voltages of 4.5 kV
● positive or negative: DUIS (dual mode ionization)
The LC and column were operated with the following factors:
● gradient elution at a flow rate of 0.5 mL/min
● column oven temperature of 40 °C
● 190-700 nm UV-VIS molecular absorption detection
All experiments were conducted in triplicate with blank solvent injections in between each set of
triplicate trials.
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2.2 Experimental Conditions of Microsomal Stability Assay

2.2.1 Chemical Reagents

The solvents were LC-MS grade and were used without further purification. Water,
acetonitrile (MeCN), methanol (MeOH), formic acid (HCOOH), and potassium phosphate buffer
were obtained from Fisher Scientific (Pittsburgh, PA, USA). The NADPH (Nicotinamide
adenine dinucleotide phosphate) Regenerating System Solution A and B were purchased from
Corning Life Science (Corning, NY, USA). Human and mouse (CD-1) microsomes were
purchased from Thermo Fisher Scientific (Waltham, MA, USA). Dimethyl sulfoxide (DMSO)
was purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA). Spin-X HPLC
filter tubes (0.22 ‐m) were purchased from Corning Inc. (Corning, NY, USA). Lastly, 2 mL
glass MS autosampler vials were purchased from (Shimadzu Corp., Kyoto, Japan).

2.2.2 Sample Preparation

1

2

A stock mix was prepared containing 282 µL of deionized water (18.2 mΩ-cm, 80
µL of potassium phosphate buffer (0.5 M, pH 7.4), 20 µL of NADPH Regenerating System
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Solution A, 4 µL of NADPH Regenerating System Solution B, and 10 µL of human or mouse
microsomes (for a final microsomal concentration of 0.5 mg/mL). The stock mix was preincubated at 37 oC for 5 min. Directly after pre-incubation, 4 µL of the drug compound (1 mM in
DMSO) was added to initiate the reaction and upon the addition of the drug compound, the
duration of the reaction was recorded. The reaction mixture was then allowed to incubate at 37
o

C. After the incubation was complete, aliquots of 50 uL of the reaction mixture were retrieved at

various time intervals (without compound): 0, 10, 20, 30, 40, 50, and 60 min. These aliquots
were added to 100 µL of ice-cold MeCN that contained 3 µM of internal standard (IS), and then
the mixture was immediately sonicated for 10 s and centrifuged at 10,000 rpm for 5 min.
Compounds 1 and 2 served as the IS for each other, thus when 1 was the target analyte, 2 was the
respective IS, and vice versa. Next 100 µL aliquots of the supernatant were transferred to Spin-X
HPLC filter tubes and centrifuged at 13,000 rpm for 5 min. Finally, 50 µL of the filtrate was
diluted 1:20 with MeOH (950 µL) and transferred to a 2 mL
l glass auto sampler vial for analysis.
Standards for the assay were prepared to establish a calibration model. Standard
concentrations for the analysis were: 1, 10, 50, 100, 200 nM, and the IS compounds were each at
a concentration of 10 nM. To minimize solvent effects, the diluent was composed of a 1:1 ratio
of water with 0.1% (v/v) HCOOH and MeCN.

2.2.3 Mobile Phases for LC-MS/MS

The mobile phase was composed of water with 0.1% HCOOH (v/v) (A) and MeOH
(B) (to prevent the formation of adducts). The gradient programming was the following: 30% B

57

(0 min) → 40% MeCN (1.5 min) → 90% B (2.0 min) → hold at 90% B (0.5 min) → return to
35% B (0.5 min) → hold at 35% B (2 min). The column temperature was 40 °C.

2.2.4 Instrumentation

The samples prepared as described above were analyzed by quantitative LCMS/MS (Shimadzu 8040, Shimadzu Corp., Kyoto, Japan) (Figure 2-3) to monitor product ion
values and establish a calibration model. The sample (10 μL) was injected into the LC-MS
instrument equipped with an ACQUITY CSH C18 column (2.1 mm × 50 mm with 1.7 µm
particle size) obtained from Waters Corp. (Milford, MA, USA). The ionization mode was APCI
mode with the corona discharge needle set to an optimal position of 5 mm. The MS was operated
with the following method parameters:
● heat block temperature at 400 °C
● drying gas flow rate of 15 L/min
● desolvation line temperature of 250 °C
● nebulizing gas flow rate of 2.0 L/min
● interface voltages of 4.5 kV
● positive ESI modes
The LC and column were operated with the following factors:
● gradient elution at a flow rate of 0.6 mL/min
● column oven temperature of 40 °C
● 254 nm UV-VIS detection
All experiments were conducted in triplicate with blank solvent injections in between each set of
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triplicate trials.
The following ion pair transitions are monitored in multiple reaction monitoring
(MRM) mode for 1 and 2 (IS), respectively: m/z 275.90 —> 164.10, m/z 275.90 —> 213.10, m/z
275.90 —> 146.10 and m/z 262.10 —> 150.10, m/z 262.10 —> 199.10, m/z 262.10 —> 132.10.
Collision energies were optimized for each transition for sensitivity.
The system control and data acquisition for the LC-MS/MS was performed on a

Dell desktop computer (Round Rock, TX, USA) and using LabSolutions software version 6.2
SP1 (Shimadzu Corp, Kyoto, Japan). All experiments represent two independent days in
triplicate.

2.3 Experimental Conditions of Pharmacokinetic Studies

2.3.1 Animal Model and Experimental Practices

Female CD-1 mice (Charles River Laboratory, Wilmington, MA, USA ) that were
four-six weeks old were used for the determination of the drug compound’s pharmacokinetic
properties. Each trial of the study was performed in triplicate. All animal experiments were
performed in compliance with the University of Wisconsin−Milwaukee or Columbia University
Institutional Animal Care and Use Committees (IACUC). Such a protocol stipulated that the
animals were housed in conditions that are free of specific pathogens and under controlled
standard environmental conditions such as humidity, temperature, and lighting (a 12 hr light and
dark cycle). The lab animals also had free access to both food and water. Before the commencing
of the experiment, the animals were allowed to adapt to their caging environment for a period of
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~5 days, to ensure their comfort.

2.3.2 Chemical Reagents

The solvents used were LC-MS grade and were used without further purification.
Water, methanol (MeOH), and formic acid (HCOOH), were obtained from Fisher Scientific
(Pittsburgh, PA, USA). The phosphate-buffered solution (PBS) and PEG400 were acquired from
Fisher Scientific (Pittsburgh, PA, USA). Dimethyl sulfoxide DMSO was purchased from
Cambridge Isotope Laboratories (Tewksbury, MA, USA). Herapin was purchased from Fisher
Scientific (Pittsburgh, PA, USA). Spin-X HPLC filter tubes were purchased from Corning
Incorporated (Corning, NY, USA). 384-well optical bottom plates and 96-well plates were
purchased from Nunc (Roskilde, Denmark). Lastly, 2 mL glass MS autosampler vials were
purchased from Shimadzu Corp. (Kyoto, Japan). For organs, the hand held LabGEN 7b Series
Portable Homogenizer; 220 VAC was obtained from Cole-Palmer (Vernon Hills , IL, USA).
CellTiter-Glo® Luminescent Cell Viability Assay was purchased from Promega (Madison, WI,
USA). Matrigel® solution (protein mixture of type IV collagen, laminin, and heparan sulfate
proteoglycan) was obtained from Corning Life Science (Corning, NY, USA).

2.3.3 Sample Preparation

Blood Plasma Pharmacokinetics
Female CD-1 mice (~20 -22 g) were dosed with either drug compound 1 or 2, at a
concentration of 10 mg/kg, that was formulated in PBS/PEG400/DMSO (19:19:2) and
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administered intraperitoneally (IP), with three mice to a group. After the drug administration and
after the animal was placed under terminal CO2, blood was periodically drawn by cardiac
puncture and collected into tubes containing 50 μL of herparin (1 mg/mL in water) to prevent
coagulation. The blood samples were then stored in liquid nitrogen until analysis was performed.
To prepare the samples for LC-MS/MS analysis, the blood samples were thawed
slowly on ice and vortexed for 10 s. Next, a 100 μL aliquot was taken and added to 300 μL cold
MeOH that was premixed with 133.3 ng/mL of internal standard (IS). This mixture was then
vortexed again for 30 s and centrifuged at 14,000 rpm for 5 min. The supernatant layer was then
spin-filtered through Spin-X HPLC filter tubes. Finally 150 µL samples of the filtrate was
transferred to a 2 mL glass autosampler vials for analysis.

Liver Pharmacokinetics
Female CD-1 mice (~20 -22 g) were dosed with either drug compound 1 or 2, at a
concentration of 10 mg/kg, that was formulated in PBS/PEG400/DMSO (19:19:2) and
administered by IP, with three mice to a group. Samples were then treated as described above.
The samples were removed from the liquid nitrogen and thawed slowly on ice. The
organ was then removed from the vial and placed on a tray, where it was rinsed with water to
remove excess blood, gently dried, and placed in a new vial. The organ was then homogenized
for 10 s on a setting that did not allow the homogenizer probe to get too hot. Careful rinsing of
the homogenizer probe was done between each sample to minimize contamination.
In the next step, 300 μL of cold MeOH containing 133.3 ng/mL of IS was added to
the homogenized organ. This mixture was then vortexed for 30 ss and centrifuged at 14,000 rpm
for 5 min. The supernatant layer was then spin-filtered through Spin-X HPLC filter tubes and the
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remaining contents of the vial were discarded. Finally, 150 µL samples of the filtrate were
transferred to a 2 mL glass autosampler vials for analysis.

Brain Pharmacokinetics
The preparation of the sample for the brain pharmacokinetics was the same as
described for the Liver Pharmocokinetics section. Note that the brain was the harvested organ.

2.3.4 Mobile Phases for LC-MS/MS

Blood Plasma Pharmacokinetics, Liver Pharmacokinetics, Brain Pharmacokinetics
The mobile phase was composed of water with 0.1% HCOOH (v/v) (A) and MeOH
(B). The gradient programing was the following: 35% B (0) → 35% MeOH (0.5 min) → 40% B
(1.0 min) → hold at 40% B (1.5 min) → 90% MeOH (2.0 min) → hold at 90% B (2.5 min) →
return to 35% B (3.0 min) → hold at 35% B (4.0 min). The column temperature was 40 °C.

2.3.5 Instrumentation

Blood Plasma Pharmacokinetic Analysis
Quantitative LC-MS/MS (Shimadzu 8040, Shimadzu, Kyoto, Japan), analysis
employed to monitor product ion values, as depicted in Figure 2-1. 10 μL of the sample was
injected into the LC–MS/MS (Shimadzu 8040, Shimadzu Corp., Kyoto, Japan) instrument
equipped with ACQUITY CSH C18 column (2.1 mm × 50 mm, 1.7 µm particle size) (Waters
Corp, Milford, MA, USA. The MS was operated with the following method parameters:
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● heat block temperature at 400 °C
● drying gas flow rate of 15 L/min
● desolvation line temperature of 250 °C
● nebulizing gas flow rate of 2.0 L/min
● interface voltages of 4.5 kV
● positive ESI mode
The LC and column were operated with the following factors:
● gradient elution at a flow rate of 0.6 mL/min
● column oven temperature at 40 °C
● 254 nm UV-VIS detection
All experiments were conducted in triplicate with blank solvent injections in between each set of
triplicate trials.
The following ion pair transitions are monitored in multiple reaction monitoring
(MRM) mode for 1 (IS) and 2, respectively: m/z 275.90 > 164.10, m/z 275.90 > 213.10, m/z
275.90 > 146.10 and m/z and 262.10 > 150.10, m/z 262.10 > 199.10, m/z 262.10 > 132.10.
Collision energy was optimized for each transition to obtain optimal sensitivity, via the
instrument computer software.
The system control and data acquisition for the LC-MS/MS was performed on a

Dell desktop computer (Round Rock, TX, USA) using LabSolutions software version 6.2 SP1
(Shimadzu Corp., Kyoto, Japan). All experiments represent two independent days in triplicate.

Liver Pharmacokinetic Analysis
The preparation of the sample for the liver pharmacokinetic analysis was the same
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as described for the Blood Plasma Pharmacokinetic Analysis section.

Brain Pharmacokinetic Analysis
The preparation of the sample for the brain pharmacokinetic analysis was the same
as described for the Blood Plasma Pharmacokinetic Analysis section.

2.4 Experimental Conditions of HPLC-UV-NMR Interfaced Scheme

2.4.1 Chemical Reagents

The solvents were LC-MS grade and were used without further purification. Water,
acetonitrile (MeCN), and formic acid (HCOOH), were obtained from Fisher Scientific
(Pittsburgh, PA, USA). Chloroform-d was purchased from Cambridge Isotope Laboratories
(Tewksbury, MA, USA). Lastly, LC-MS grade toluene was purchased from Sigma-Aldrich (St.
Louis, MO, USA).

2.4.2 Mobile Phases used in Interfaced System

The mobile phase was composed of water with 0.1% HCOOH (v/v) (A) and MeCN
(B). The gradient programing was the following: 0% MeCN B (0.0 min) → 15% MeCN (5.0
min) → 30% MeCN B (3.0 min) → 45% MeCN B (3.0 min) → return to 0% MeCN (3.0 min) →
hold at 0% MeCN B (6.0 min).

64

2.4.3 Sample Preparation

A 100 µM sample solution of toluene in chloroform-d was prepared from a 1 mM
stock solution. The sample was transferred to a 2 mL glass autosampler vial for analysis. Lastly,
2 mL glass MS autosampler vials were purchased from (Shimadzu Corp., Kyoto, Japan).

2.4.4 Instrumentation

NMR
PicoSpin Model 45 and Model 80 benchtop NMR instruments (Thermo Fisher
Scientific, Madison, WI) were used. A diagram of the components of the NMR instrument is
found in Figure 2-4. The instrument was shimmed with LC-MS grade water twice weekly and
water was injected in the instrument holding cell, during storage. All samples, including those
for shimming, were injected via the inlet port, a diagram of which is depicted in Figure 2-5.
Digital Valve Sequence Programmer
The Digital Valve Sequence Programmer (Model DVSP-4, Valco Instruments,
Houston, TX, USA) (Figure 2-6) was wired as described in the manual (4). The depicting of the
terminals and their wiring can be found in Figure 2-7a (4) with an image in Figure 2-7b. The sixport, two -position valve (Figure 2-8) was connected to the DVSP (three wires — black, red, and
green). Next, the black (INJECT) wire was corrected to the NO (“normally open") terminal of
the A relay. The red (LOAD) wire was connected to the NO terminal of the C (“common”) relay.
Lastly, the green (GROUND) wire was connected to the C terminal of the C relay. Times were
set on the DVSP to synchronize the elution time of the analyze from the column, i.e., to
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automatically switch the FIA from LOAD to INJECT.

HPLC
A separation of the sample was performed using the Agilent 1100 HPLC (Santa
Clara, CA, USA) (Figure 2-9) (5). The sample (10 μL) was injected into the HPLC instrument.
The HPLC was operated with the following method parameters:
● Agilent TC-C18 column (4.6 mm x 250 mm, 5 µm particle size) (Agilent
Technologies, Santa Clara, CA, USA)
● gradient elution at a flow rate of 0.3 mL/min
● column oven temperature at 40 °C
● 190-700 nm UV-VIS detection
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2.5 Figures and Tables:

Figure 2-1a. Schematic diagram of Shimadzu 8020 LC-MS/MS (adapted from Shimadzu)
(1).

Figure 2-1b. Schematic diagram of Shimadzu 8040 LC-MS/MS (1).
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3

1

2

Figure 2-2b. Image of the
corona discharge needle (3) on
the MS instrument.

Figure 2-2a. Image of the corona
discharge needle setting on the MS
instrument. 1 = distance intervals
(mm) for the adjustment of the
corona discharge needle. 2 = the
corona discharge needle sample
inlet.
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Figure 2-3. Schematic diagram of Shimadzu 8040 LC-MS/MS (Adapted from Shimadzu) (1).
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Figure 2-4. Diagram of the picoSpin NMR components (3).
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Figure 2-5. Diagram of the picoSpin NMR inlet port and components (3).
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Figure 2-6. Schematic of the DVSP instrument (Adapted from Digital Valve Sequence
Programmer Instruction Manual) (4).
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Figure 2-7a. Diagram depicting
the terminal strip connections
used for the DVSP (Adapted from
Digital Valve Sequence Programmer
Instruction Manual) (4).

Figure 2-7b. Image of the terminal
strip connections used for the DVSP.
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Figure 2-8. Diagram of the six-port valve that interfaced the HPLC and NMR.
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Figure 2-9. Diagram of the Agilent 1100 HPLC instrument and components (5).
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Table I. A comparison of the properties of picoSpin models 45 and 80 (Adapted from
ThermoFisher Scientific) (3).
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CHAPTER 3. RESULTS AND DISCUSSION

3.1 Characterization of Novel Halogenated Alkylating Compounds by Liquid
Chromatography Single Quadruple Mass Spectrometry

3.1.1 Mass Spectrometry Ionization Sources – An Overview of the Theory & Practice

Although there are several types of ionization modes available to use with MS analysis,
the two types of ionization sources available on the instrument models used were
electrospray ionization (ESI) and atmospheric pressure ionization (APCI), in addition to a dual
mode setting that allows the option of both ionization modes used simultaneously. A diagram of
depicting compound property and ionization source compatibility is shown in Figure 3-1 (1).

3.1.2 Method Optimization

Achieving ionization of halogenated compounds such as 1 and 2 requires the careful
selection of ionization source as well as the optimization of the ionization source parameters,
such as corona discharge needle distance from the corona needle. Typically, for ESI mode, it is
favorable for ionization for the placement of the corona discharge needle to be further away from
the cone while for APCI mode, it is more favorable to have the corona discharge needle closer to
the cone. For dual ionization mode, a medium distance is best for a compromise between the two
ionization settings, and though this allows for both ionization sources to be used simulatiously,
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the signal produced by each respective ionization mode is weaker than if the ionization mode
settings were optimized for individual ionization mode use.
Next the calculation for the gradient times (based on the column dimensions, column
packing, and flow rate), is determined. This information is used to estimate the void volume and
retention time to ensure that there is adequate time given for sample elution as well as column
reequilibration. Figure 3-2a (2) defines the signals produced at critical time points of elution such
as void time (tm) and retention time (tR) and Figure 3-2b shows these signals in an experimentally
acquired chromatograph.

3.1.3 Characterization of Novel Compounds

Calcd. ([M+1]+): 138.0681 Calcd: ([M+1]+): 220.479

Calcd: ([M]+): 176.0280
Found: ([M]+): 176.150

Calcd. ([M+1]+): 292.01
Found: ([M+1]+):

292.10

Naphthalene precursors 5 and 6
In order to qualitatively confirm a particular compound using MS analysis, it is important
to determine the molecular mass/charge (m/z) as well as to predict the expected ionization and
the peak ratio of isotopes. For example, in the case with 5, the expected isotope peak pattern for
a Br is about a 1:1 peak ratio (of 79Br+:81Br+. For a compound with Br2, the pattern would be
expected to be about a 1:2:1 ratio of 79,81Br+:79,79Br+:81,81Br+. Similarly, for chlorinated compound
such as 6, the isotope peak pattern is about 3:1 of 35Cl and 37Cl. For a compound with Cl2, the
pattern would be expected to be about a 9:6:1 ratio of 35,35Br+:35,37Br+:37,37Br+.
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The signal of the first sample, 6, was detected on the PDA plot as seen on Figure 3-3a
and the time point extracted on the MS spectrum (Figure 3-3b) based on the signal produced on
the chromatogram. The results should have shown the ionization of the dimerized species at a 3:1
ratio, however this was not the case as the compound did not ionize. Retrospectively, after the
successful ionization of similar compounds analyzed later, the most likely issue with the
experiment was the low concentration (250 µM) of the compound in the injected sample, which
may not have been sufficiently concentrated to produce a signal by MS analysis. Increasing the
concentration to 1 mM and in addition, using dual or APCI mode of ionization with optimized
corona discharge needle positioning would likely have resolved the ionization issue with 6.
Upon making the described change in ionization mode (from ESI to APCI) and therefore
also the corona discharge needle positioning (optimized to 10 mm), 6 was successfully ionized
using simple flow injection (no column) and whist retaining the concentration of 250 µM used
previously. In this manner, 6 was successfully detected in the MS spectrum Figure 3-3c (mass
region of interest). After the ionization of 6 was established by flow injection, a column gradient
method was executed once again confirming the compound as seen in the PDA plot and MS
spectrum (Figures 3-4a and b, respectively).
As described above, for APCI analysis, the corona needle position was optimized to the
10 mm through a series of runs of the sample compound at various corona discharge needle
positions. Spectra of corona needle positions by intervals of 1 mm are depicted in Figure 3-5 a-i.
The setting of 10 mm produced the strongest and most abundant signal for the isotopic ratio of
interest, under APCI mode, as seen from Figure 3-6, which summaries the signal intensity vs.
corona discharge needle positioning.
Currently compounds 3 and 4, which contain bromines, remain unsuccessfully analyzed
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as mass spectrometry analysis was not successful with the brominated compound 5. Future work
can continue with instrumental conditions optimized for the ionization of such brominated
naphthalene compounds and hence 3, 4, and 5.

Methoxybenzene Analogues 7, 8, 9, and 10

7
Calcd: ([M+1]+): 138.0681

8

9

Calcd: ([M+]: 263.9637
Found: ([M-OH]+): 247.00

Calcd: ([M+1]+): 281.9308
Found: ([M+1]+): 282.00

10
Calcd: ([M]+): 292.0120
Found: ([M]+): 292.10

Figure 3-7 a and b are the PDA plot and MS spectrum, respectively, of the uniodinated 10
starting material. Figure 3-8 a and b on the other hand are the PDA plot and MS spectrum
respectively of 9. Both the uniodinated and iodinated compounds ionize in the positive mode and
lose an OH- as evidence from the m/z of 121 for the uniodinated 9 and 247 for the iodinated 9.
Note that the I isotope peak produces a single peak and thus there is no peak ratio to evaluate.
Lastly, both compounds ionized in APCI mode with the corona discharge needle optimized to 5
mm.
Compounds 7 and 8 were analyzed by first achieving a signal on the PDA spectrum as
seen in Figures 3-9a. This was completed by increasing the concentration of the sample injected
to 1.0 mM. Relaying this to the LC chromatogram and analyzing the MS spectrum (Figure 3-9 b)
at about 2.9 min produced a 3:1 abundant peaks (76%:24%) for Cl at m/z = 282 and 284. The
spectrum was also confirmed as it matched the predicted spectrum for the compound as seen in
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Figure 3-10 (3).
Lastly is the analysis of 10 and an unknown sample. Attempting ESI mode as expected
did not produce ionization. Two changes were made to remedy this issue. First the sample was
dissolved in MeOH rather than ACN (and the mobile phase was also changed to MeOH), to
better assist with ionization. Initially MeOH was avoided as the sample solvent due to potential
solubility issues as compared to ACN however it was determined compatible. Secondly,
switching the ionization mode to dual ESI/APCI modes and optimizing the corona needle
position to be at 10 mm produced successful ionization of both compounds in the positive mode
(Figure 3-11 a and b). The N on 10 (m/z = 291) is proposed to be protonated. Based on the
structure of 10, the unknown sample was determined to be a byproduct of the drug compound
with an m/z = 221. Again, the I has a single abundant isotope (Figure 3-12 a and b).

Found: ([M-1]-): 221.16

3.2 Analysis of In Vitro Microsomal Stability Assay

3.2.1 Method Optimization
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1,

2,

LC Gradient
First the transition ions are monitored in MRM mode for positive and negative ionization
events (Figure 3-13 a and b) and the collision energy (CE) for these transition ions (Figure 3-14 a
and b) in total and for positive mode, for 2 as determined by LabSolutions software. In addition,
various LC gradient methods were attempted in order to balance both length of LC run as well as
achieve sufficient separation and peak shape. These changes were established based on the
determination of the void volume, which was calculated to be ~0.2 min (although the exact
volume is difficult to calculate because the packing space is unknown). The spectrum for a blank
ACN sample is depicted in Figure 3-3.This can be seen in Figures 3-(16-18) a-c with an
improvement in peak resolution from gradient programming method 1 to 2 by amending the
method to have a longer hold time and then a reduction in run time from 9 min to 4 min in
gradient programming method 2 to 3 by delaying the gradient. Attempts shorter than 4 min
resulted in a reduction in peak resolution so it was determined that method 3 was the optimized
gradient programming method.

LC Peak Shape
As MeOH may cause adducts to form, seen in Figure 3-17a as the cause of tailing in the
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spectra presented. Thus switched to an ACN as solvent system, while the sample solvent
remained MeOH to assist with solubility, improved the peak shape distortion, this improvement
seen in Figure 3-18 a and b. Also, peak shape distortions also appeared once again, as seen in
Figure 3-19a, depicting the analysis of a 5 nM concentration of IS and 500 nM concentration of 6
in pure ACN. To resolve these peak, it was determined to be caused by solvent effects in the
sample, therefore water was added to minimize these solvent effects. A clear improvement can
be seen when the water:MeOH ratio of the same sample in a 1:3 water:MeOH, as seen in Figure
3-19b. However, one consideration worth noting for such a change is the stability of the
compound in water. It was determined from previous studies by other investigators that 2 is not
stable in water due to hydrolyzation, and so to prevent this, the samples were prepared the day of
analysis.

Calibration Curve
For the calibration curve, initially standard samples were prepared of 5, 50, 500, 1000,
and 5000 nM CP + 500 nM IS concentration, to encompass the calibration curve concentration
requirements for both the microsomal stability assay as well as the pharmacokinetic study to
come later. Such intervals of standard concentration to IS concentration proved to be too large
and as a result the IS drowned the signal of the lower concentration CP, as seen in in the poor
calibration curve fit in Figure 3-20 a-c. For this reason, it was decided to create two separate
calibration curves, with the microsomal stability assay calibration curve using the concentrations
of 1, 10, 50, 100, and 200 nM CP + 10 nM IS, the integration and manual calculations displayed
for three trials of each standard concentration and the corresponding calculations as acquired
from LabSolutions software in Figure 3-21a and the calibration curves displayed in Figure 3-21
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b-d. The manual calculations that were completed confirmed the validity and accuracy of the
calculations acquired from LabSolutions software for this particular calibration curve.

Concentrations/Injection Volume
Tailing was also present in the spectra and caused by injection volume (concentration).
To amend this issue, the sample injection volume was increased from 20 µL to 50 µL, using the
optimized sample preparation mentioned previously at concentrations of both 125 nM and 5 nM
of CP. The peak shape improved from this concentration change as evidence in Figure 3-22 and
24, a-b. Most likely such tailing is due to poor signal resolution as a factor of sensitivity.

3.2.2 Calculations for the Determination of Drug Stability - An Overview of the Theory &
Practice

The peak area ratios of the IS and test compound were calculated for every time point and
the natural log of the ratio was then calculated and plotted as a function of time in order to
determine the linear slope (k). The metabolic rate (k*C0/C), half-life (0.693/k), and internal
clearance (V*k) were also calculated, where k is the slope, C0 is the initial concentration of test
compound, C is the concentration of microsomes, and V is the volume of incubation (μL) per
microsomal protein (mg). As the experiments were performed in triplicate, the values for each
time point were averaged prior to the calculation.
For first-order kinetics, the slope eventually decreases to zero and the length of the halflife is constant, independent of concentration. The rate law for first-order kinetics is defined as

[A] = [A]0e-kt
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and rearranged to solve for the half-life (t1/2) = ln/2 = 0.693/k.
Figure 3-24 (4) shows a graphical distinction between each half-life for first-order
kinetics and in Figure 3-25 a and b, the experimental data for the stability assay is correlated to
each respective half-life, which from the data, it can be determined that the t1/2 exp for human
microsomes was 77.06 min and the t1/2 ln was 75.34 min. Meanwhile the t1/2 exp for mouse
microsomes was 33.00 min and the t1/2 ln was 33.32 min.

3.3 Analysis of In Vivo Pharmacokinetic Studies

3.3.1 An Overview of the Theory & Practice

To better evaluate the stability and clearance of a drug in vitro and in vivo, several
experiments were conducted to compare the parameters of 1 to those of 2. Figure 3-26 a and b
show the results of a pharmacokinetic study on plasma compound concentration (ng/mL) vs.
time (min) for 1 and 2, finding that 2 had about twice the length of half-life as that of 1.These
experiments for 1 were completed at an earlier time, therefore the analysis presented in this
evaluation are primarily regarding 2, however previous data is used in this presentation in a
comparative manner. Several organs of the mouse model were harvested to better understand the
distribution and clearance of the drug compound 2. Although at this time not all information is
conclusive, the data that has been established is promising.

3.3.2 Blood Plasma Sample Analysis
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Figure 3-27 a and b plot the pharmacokinetic results for blood plasma in mice, and as
shown with the two experimental trials, there is good reproducibility and in addition both
compounds (1 or 2) were readily detected in plasma with a tmax value of ~3 min. Although both
compounds showed rapid drug clearance, the introduction of a CH3 in 2 greatly increased the
duration time of the drug in the plasma with a t1/2 of 8.84 min, which is almost two times that of
1 (t1/2 = 4.92 min). The rate of elimination for 1 in the blood is considered fast (at a rate of Erate =
0.141 min−1), while the rate of elimination of 2 takes about twice as long (Erate = 0.078 min−1). 2
showed an area under the curve (AUC) of 16253 ng•min/mL, which is significantly higher than
that of 1 (10883 ng•min/mL). These conclusions can be seen from Figures 31a and 31b.

3.3.3 Liver Sample Analysis

Figure 3-28 shows the pharmacokinetics results for liver, plotting the compound
concentration (ng/mL) vs. time (min). The results show excellent reproducibility as seen by the
minimal error bars (not including the first time point which is difficult to experimentally
administer precisely. The decay also closely follows that of the plasma pharmacokinetic data, so
again confirming reproducibility.

3.3.4 Brain Sample Analysis

Figure 3-29 shows the pharmacokinetics results for brain, plotting the compound
concentration (ng/mL) vs. time (min). Interestingly, as there is a relatively high concentration of
the CP in a non-targeted organ such as in this case, the brain, this brings into consideration
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various adverse effects that may be a negative factor of the CP crossing the blood brain barrier
(BBB). On the other hand, the ability of the CP to penetrate the BBB may bring rise to future
studies on cancers that target the brain such as glioblastoma. Such a study could include similar
stability and pharmacokinetic studies as well as the possibility for tissue imaging through MSimaging methods such as MALDI (matrix assisted laser desorption ionization) imaging to better
understand the drug distribution in the organ as well as to apply quantifiable measurements to
these areas of drug distribution within the tissue sample.

3.4 Analysis of HPLC-UV-NMR Interfacing Scheme

3.4.1 HPLC, UV, and NMR - An Overview of the Theory and Practice

Interfacing HPLC to NMR is a powerful combination, particularly for pharmaceutical
applications. First, it condenses three different techniques into a single, automated system that
requires minimal sample preparation. Furthermore, detectors such as MS can be incorporated
into the system because the NMR measurement is non-destructive. Many pharmaceutical
approaches that traditionally rely on LC-MS analysis are not adequate for highly reactive or
volatile metabolites. Moreover, the interfacing system is complimentary and provides structural
information that when assessed together, one method alone could not achieve (5).

3.4.2 NMR Component Optimization
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To allow for the optimization of each component of the system, spectra can be verified
after each interfacing instrument. In the case of the NMR instrument, it was shimmed once a
week at a minimum, using water (Figure 3-30). Figure 3-31 a and b are spectra of toluene (10
mM) in deuterated chloroform injected into the instrument after 64 and 512 scans, respectively.
As expected, it can be seen from this scan study that more scans increase the S/N ratio. To
confirm the acquired spectra, the shift values were compared to a table of published values. In
Table I (3), shift values can be found for H-NMR for various solvents. In Figure 3-32, an
impurity peak found in the spectrum (512 scans) is noted toluene in chloroform (10 mM). Based
on Table I, it can be speculated that the peak defined in Figure 3-32 under the right arrow is most
likely water (at a 4 ppm shift) and dichloromethane (at a 5.30 ppm shift). Lastly, the integrated
spectrum (512 scans) of toluene (10 mM) in chloroform can be found in Figure 3-33 and matches
the expected H ratio of 5:3 for CH3:C6H5.

3.4.3 Interfacing LC-NMR: Flow Injection Manifold Design

Although there are several methods of coupling the various instruments, LC-NMR
hyphenation typically includes capillary tubing, and a switching value interface (manual or
automated). In addition, the interface may be a flow of the sample that is continuous, “on-flow,”
or “(direct) stop-flow” or the more advantageous “loop storage/loop transfer.” The details of the
various flow methods can be found in the Introduction chapter. And as mentioned previously,
this work incorporates “on-flow,” “stop-flow,” a “loop transfer” in that the sample is captured
the eluted from the NMR, the spectra is acquired in a static state while in the NMR cell, and the

89

remaining flow is diverted to waste (6). Such a LC-NMR system can allow for the analysis of a
complex drug sample. Due to the efficient separation from the LC component, the NMR
instrument can provide interference free data. In addition, NMR is non-destructive and it can also
detect molecules with low molecular weights. NMR can provide both qualitative as well as
quantitative information (as the spectral peaks can be integrated to the solvent shift) (7-8).
Adding an addition layer and coupling LC to both NMR and MS, whether in-series or inparallel, offers the advantage of two complimentary and powerful tools in one system. However
although there are significant advantages of LC-NMR-MS, one of the major concerns with such
a hyphenation is the potential solvent suppression from the NMR signal if non-deuterated
solvents are utilized or if this suppression is no resolve. Additionally, NMR is far less sensitive
than the MS detector and also cannot detect NMR silent functional groups. Therefore, much
research has occurred in the past several decades to interface NMR and MS and establish
experimental conditions compatible to run using both detectors.
In recent times, groups have utilized LC-NMR-MS for the determination of endogenous
drug metabolites, multiple generations of ion fragments, determination of the parent drug, and
many other applications (8). As described in detail in the Introduction section, nearly all the
historical improvements of LC-NMR were aimed at improvements to parameters such as
sensitivity. This was first done by way of component design (thin-walled Teflon tubes and
inserts) (1970s and 1980s) (9-10). From this point, attention was focused on column
improvements (1990s -2000s) to amplify the analyte signal (11-12). In addition, flow cells were
optimized to be smaller and be enabled for temperature control. Finally continuous flow
development and throughput was fine-tuned (13).
Although data for the interfaced LC-NMR system is not presented at this time, the
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previous portions have described the initial steps of optimization for the concept. In addition,
further work can be done on the optimization of the HPLC-UV detector, which requires solvent
gradient programming as presented in previous portions of this work, and timing studies to
ensure that the sample is held in the NMR sample holding coil at the correct time, shortly after
elution from the column. Furthermore, along with NMR, other detectors such as MS can be
interfaced both in parallel by varying the widths of the lines to accommodate for varied sample
volume required due to varying instrument sensitivity (14).
LC-NMR-MS is beneficial in that allows significant tools that not only expands the
analysis of the sample, but also allows for high throughput analysis. The main benefit of
hyphenating LC-MS is to extrapolatory information such as the sensitivity that MS offers and the
structural information from both instrumental methods in a single experiment. As mentioned in
the Introduction chapter, there are many varieties of flow for LC-NMR-MS hyphenation,
including splitting the flow and coupling in-series preconcentration methods (SPE) and inparallel analysis (LC-NMR coupled to UV, MS). In general, hyphenation presents issues such as
ascribing results to a detector (if done in-series), pressure differences between detectors, and
synchronization.
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3.5 Figures and Tables

Figure 3-1. A diagram depicting compatible ionization sources for particular compound
characteristics such as size molecular mass and polarity (1).

92

Figure 3-2a: A labeled chromatogram defining the signals produced at critical time points (tm)
and (tR) (2).

tg

tm

Figure 3-2b. An experimentally acquired chromatogram that labels the terms (tm) and (tR) as
noted above.
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Figure 3-3a. PDA plot of compound 6 using a column, under APCI mode.

Figure 3-3b. MS spectrum of compound 6 by flow injection, under APCI mode.
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Figure 3-3c. MS spectrum region of interest for compound 6, depicting the Cl isotopic peaks of
m/z = 176 and 178, at a 3:1 ratio, under APCI mode.
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Figure 3-4a. PDA plot of compound 6 using a column, under APCI mode.

Figure 3-4b. MS spectrum of compound 6 by flow injection, under APCI mode.
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Figure 3-4c. MS spectrum region of interest for compound 6, depicting the Cl isotopic peaks of
m/z = 176 and 178, at a 3:1 ratio, under APCI mode.
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Figure 3-5a. Mass spectrum chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 2 mm.
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Figure 3-5b. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 3 mm.
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Figure 3-5c. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 4 mm.
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Figure 3-5d. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 5 mm.
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Figure 3-5e. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 6 mm.

102

Figure 3-5f. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 7 mm.
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Figure 3-5g. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 8 mm.
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Figure 3-5h. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 9 mm.
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Figure 3-5i. Flow injection chromatograph and MS spectrum in APCI mode with corona
discharge needle set to 10 mm.
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Figure 3-6. A summary of the relative signals produced at different corona discharge needle
settings in APCI mode for compound 6.

107

Figure 3-7a. PDA plot of uniodinated compound 7.

Figure 3-7b. An MS spectrum of uniodinated compound 7, in APCI mode with the corona
discharge needle set to 5 mm.
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Figure 3-8a. PDA plot of iodinated compound 8.
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Figure 3-8b. An MS spectrum of iodinated compound 8, in APCI mode with the corona
discharge needle set to 5 mm.
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Figure 3-9a. A chromatograph of compound 8.

Figure 3-9b. An MS spectrum of compound 9, in APCI mode with the corona discharge needle
set to 10 mm.
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Figure 3-10. An expected MS spectrum, with emphasis on the isotopic peak ratio for compound
9 (3).
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Figure 3-11a. A chromatograph of compound 10.

Figure 3-11b. An MS spectrum of compound 10, in dual ionization mode with the corona
discharge needle set to 10 mm.
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Figure 3-12a. A chromatograph of unknown compound.

Figure 3-12b. An MS spectrum of unknown compound, in dual ionization mode with the corona
discharge needle set to 10 mm.
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Figure 3-13a. MRM spectrum for compound 2, in positive mode.

Figure 3-13b. MRM spectrum for compound 2, in negative mode.
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Figure 3-14a. Total CE optimization for compound 2 under MRM.

Figure 3-14b. CE optimization for compound 2 under MRM, in positive mode.
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Figure 3-15a. Chromatograph of first attempt at gradient programming, with an 8 min column
run.

Figure 3-15b. The gradient programing time events for the first method for gradient
programming, with an 8 min column run.

Figure 3-15c. Gradient conditions for the first method for gradient programming.
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Figure 3-16a. Chromatograph of second method at gradient programming, with a 9 min column
run.

Figure 3-16b. The gradient programing time events for the first method for gradient
programming, with a 9 min column run.

Figure 3-16c. Gradient conditions for the second method for gradient programming.
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Figure 3-17a. Chromatograph of third method at gradient programming, with a 4 min column
run.

Figure 3-17b. The gradient programing time events for the third method for gradient
programming, with a 9 min column run.

Figure 3-17c. Gradient conditions for the third method for gradient programming.
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Figure 3-18a. Chromatograph depicting peaks detected using a MeOH organic mobile phase.

Figure 3-18b. Chromatograph depicting peaks detected after switching to ACN as the organic
mobile phase.
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Figure 3-19a. 5 nM IS + 500 nM IS compound prepared in MeOH, no water.

Figure 3-19b. 5 nM IS + 500 nM compound prepared in 1:3 water:MeOH.
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Figure 3-20a. Precision of the IS concentration added to each standard for the microsomal
stability assay calibration curve.

Figure 3-20b. A calibration curve with compound 2 and no IS.

Figure 3-20c. A calibration curve with compound 2 and 10 nM IS.
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Figure 3-21a. The microsomal stability assay calibration curve standard concentrations and
respective concentrations for three trials, mean and standard deviation as determined by manual
calculation by comparison of area integration and the calculations as acquired from LabSolutions
software.

Figure 3-21b. Precision of the IS concentration added to each standard for the microsomal
stability assay calibration curve as established by using the amended standard concentrations.
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Figure 3-21c. A microsomal stability study calibration curve with the amended standard
concentrations with compound 2 and no IS.

Figure 3-21d. A microsomal stability study calibration curve with the amended standard
concentrations with compound 2 and 10 nM IS.
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IS

CP

Figure 3-22a. 125 nM compound 2 + IS with an injection volume of 50 uL.

Figure 3-22b. 5 nM compound 2 + IS with an injection volume of 50 uL.
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Figure 3-23a. 125 nM compound 2 + IS with an injection volume of 20 uL.

Figure 3-23b. 5 nM compound 2 + IS with an injection volume of 20 uL.
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Figure 3-24. A depiction of graphical half-life determination for first-order kinetics (4).
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Figure 3-25a. Microsomal stability assay for compound 2 results depicting concentration (ppb)
at various time points min, for human and mouse microsomes.
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Figure 3-25b. Microsomal stability assay for compound 2 results depicting percentage ln
concentration ratio at various time points min, for human and mouse microsomes.
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Figure 3-26a and b. Graph of pharmacokinetic study on plasma compound concentration
(ng/mL) vs. time (min) for compound 1 (A.) and compound 2 (B).
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Figure 3-27a. Graph of pharmacokinetic study on plasma compound concentration (ng/mL) vs.
time (min), experiment 1.
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Figure 3-27b. Graph of pharmacokinetic study on plasma compound concentration (ng/mL) vs.
time (min), experiment 2.

130

Liver
Compound (ng/mL)

4000

3000

2000

1000

0
0.

30.

60.
Time (min.)

90.

120.

Figure 3-28. Graph of pharmacokinetic study on liver compound concentration (ng/mL) vs. time
(min).
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Figure 3-29. Graph of pharmacokinetic study on brain compound concentration (ng/mL) vs.
time (min).
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Figure 3-30. An NMR spectrum of a water peak injected into the NMR instrument and analyzed
at 62 scans.
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Figure 3-31a. An NMR spectrum of a 10 mM sample of toluene in deuterated chloroform
injected into the NMR instrument and analyzed at 62 scans.

Figure 3-31b. An NMR spectrum of a 10 mM sample of toluene injected into the NMR
instrument and analyzed at 512 scans.
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Figure 3-32. An NMR spectrum (512 scans) of toluene (10 mM) in chloroform with two
impurities defined.
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Figure 3-33. An integrated NMR spectrum (512 cans) of chloroform (10 mM) in toluene.
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Table I. A table of H-NMR shifts for various solvents (3).
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CHAPTER 4. CONCLUSION

There were several objectives of this thesis. The first was to successfully ionize the
halogenated compounds in order to characterize them by mass spectrometry (MS) (single
quadrupole). This allows for the compound to be confirmed during the synthesis process and
allows for the quantification of the compound in later stages of research and development. The
second goal included the quantification of a drug compound which included an animal study,
assay development, and finally the optimization of MS/MS instrument parameters (triple
quadrupole).
To achieve efficient ionization of the halogenated alkylating agents, electrospray
ionization (ESI), atmospheric pressure chemical ionization (APCI), and dual mode ionization
combining the two ionization modes (DUIS) were applied. It was determined that efficient
ionization and highest signal intensity were obtained for the compounds when APCI mode was
set at an optimized corona needle position of 10 mm. This work suggested that these halogenated
alkylating agents could be best analyzed using APCI ionization mode and at the optimized
instrumental conditions. Finally, we successfully analyzed compounds 3-10 by mass
spectrometry.
For the pharmacokinetic study, we first optimized the instrument parameters for signal
intensity and established calibration curve for the proceeding studies. Then, we carried out an invitro stability assay where the samples were quantitatively characterized by MS/MS. Compound
2 showed a t1/2 of 77.06 min in the presence of human microsomes and a t1/2 of 33.00 min in the
presence of mouse microsomes.
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Followed by microsome stability study, we determined pharmacokinetic parameters of
compound 2. The mice were injected with compound 2 at different time point, sacrificed, and
their blood, liver, and brain organs harvested. The organs were then homogenized, samples
processed, and quantified by MS/MS. Our data showed that introduction of a CH3 group (2)
greatly increased the duration time of the drug in the plasma with a t1/2 of 8.84 min, which is
almost two times that of the parent compound 1 (t1/2 = 4.92 min). The rate of elimination for 1
(Erate = 0.141 min−1) in the blood is faster that of 2 (Erate = 0.078 min−1). Compound 2 showed an
area under the curve (AUC) of 16253 ng•min/mL, which is significantly higher than that of 1
(10883 ng•min/mL). The half-life of compound 2 in mice liver and brain is 17.769 min and
13.86 min, respectively.
Future work includes modification of the parent compound 2 by introducing more
lipophilic substituents to further improve the in vivo duration time and characterization of
modified compounds with MS, including pharmacokinetic assays and quantifications. The
pharmacokinetic data of compound 2 indicated a relatively high concentration of the compound
in mice brain, which suggested that 2 is able to cross the blood brain barrier (BBB). Thus, 2 can
be a potential candidate for further research towards brain cancers, including glioblastoma. We
would also consider tissue imaging through MS-imaging methods such as MALDI (matrix
assisted laser desorption ionization) imaging to better understand the drug distribution in
different organs as well as to apply quantifiable measurements to determine drug distribution
within different tissue samples.
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